Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.
Q3 earnings, Fed rate decision, Budget to steer Dalal Street this week
Stock market is gearing up for an eventful week ahead where key triggers such as quarterly earnings from corporates, the US Fed interest rate decision